Overview

A Study of Mirikizumab in Healthy Chinese Participants

Status:
Completed
Trial end date:
2020-12-11
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety of the study drug known as mirikizumab. The study will investigate how the body processes the study drug. It will last up to about 4 months for each participant.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Mirikizumab